Compounded GLP-1 drops or tablets vs injections: do the oral versions work?

Short answer: No — compounded “GLP‑1 drops” or homemade tablets are unlikely to reliably work the way injected or FDA‑approved oral GLP‑1 medicines do, and they carry safety and legal risks. Use FDA‑approved formulations or discuss alternatives with your clinician.

Why—key points

• Peptides are fragile and poorly absorbed by the gut. GLP‑1 drugs are large peptide molecules that are normally destroyed in the stomach/intestine and/or not readily absorbed into the bloodstream.
• Approved oral technology matters. Rybelsus (oral semaglutide) is the only widely approved oral GLP‑1. It uses a special absorption enhancer (SNAC) and a formulation proven in clinical trials (PIONEER program). That special chemistry is what makes any oral peptide effective at all; a plain compounded tablet or “drops” usually lack that technology.
• Injections are more predictable. Injectable GLP‑1s (Ozempic, Wegovy — semaglutide; Mounjaro — tirzepatide; Trulicity — dulaglutide; Victoza/Saxenda — liraglutide) have well‑studied dosing, predictable blood levels and known safety profiles.
• Compounded products lack evidence. Compounded semaglutide or tirzepatide drops/tablets have not been tested in controlled trials for absorption, efficacy, or safety. You don’t know if you’re getting the stated dose, any bioavailability, or contaminants.
• Safety/regulatory risks. Compounded drugs aren’t reviewed by the FDA the same way brand products are. Dosing errors, contamination, improper storage (peptides often require refrigeration), and fraud are real concerns. Adverse effects (nausea, hypoglycemia with other meds, pancreatitis, gallbladder problems, etc.) could occur without medical supervision.

How the approved options differ

• Rybelsus (semaglutide oral): proven effective in trials for glucose lowering and weight loss; must be taken exactly (fasted with a small sip of water, wait ~30–60 minutes before eating/other meds).
• Ozempic and Wegovy (injectable semaglutide): once‑weekly injections; Wegovy is the higher‑dose indication for weight management.
• Mounjaro (tirzepatide injection) and Zepbound (tirzepatide for weight): once‑weekly GIP/GLP‑1 agonist with strong weight‑loss results in trials.
• Other injectable GLP‑1s: Trulicity (dulaglutide), Victoza/Saxenda (liraglutide), Bydureon (exenatide) — all have known, regulated profiles.

If you’re considering compounded GLP‑1 drops/tablets

• My strong recommendation: don’t. Prefer FDA‑approved products prescribed and monitored by a clinician.
• If cost/access is the reason: talk to your prescriber about alternatives — generics where available, switching to an injectable if appropriate, manufacturer copay programs or patient assistance, or legitimate oral Rybelsus if appropriate for your condition.
• If you still consider a compounding pharmacy: verify the pharmacy’s credentials and state board inspection history, ask for evidence of product testing and stability data, confirm cold‑chain/storage procedures, and insist on lab testing of the final product. Even then, lack of clinical data means risk.

What to do next

• Discuss with your doctor/endocrinologist what goal you have (blood sugar control vs weight loss) and which approved medication is right.
• If affordability is the barrier, ask about patient assistance programs (Novo Nordisk, Eli Lilly, etc.), samples, or alternative treatment strategies.
• Avoid buying peptide drops/tablets from clinics or online sellers that won’t give clear documentation on handling, testing, or sourcing.

If you want, tell me:

• Is this for diabetes management or weight loss?
• Are you being offered a specific compounded product (brand, pharmacy)? I can give more tailored advice and list assistance options for approved meds.